[HTML][HTML] Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications
U Testa, G Castelli, E Pelosi - Medicines, 2019 - mdpi.com
Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
FC Hamdy, JL Donovan, JA Lane… - … England Journal of …, 2023 - Mass Medical Soc
Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …
[HTML][HTML] Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy
SF Mungovan, SV Carlsson, GC Gass… - Nature Reviews …, 2021 - nature.com
Urinary incontinence is a common and predictable consequence among men with localized
prostate cancer who have undergone radical prostatectomy. Despite advances in the …
prostate cancer who have undergone radical prostatectomy. Despite advances in the …
MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis
M Ahdoot, AR Wilbur, SE Reese… - … England Journal of …, 2020 - Mass Medical Soc
Background The use of 12-core systematic prostate biopsy is associated with diagnostic
inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer …
inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer …
[HTML][HTML] Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C Parker, E Castro, K Fizazi, A Heidenreich… - Annals of …, 2020 - annalsofoncology.org
Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Background Very long-term mortality in men with early prostate cancer treated with surgery
versus observation is uncertain. Objective To determine long-term effects of surgery versus …
versus observation is uncertain. Objective To determine long-term effects of surgery versus …
[HTML][HTML] Association of plant-based diet index with prostate cancer risk
Background Plant-based diets are associated with multiple health benefits and a favorable
environmental impact. For prostate cancer, previous studies suggest a beneficial role of …
environmental impact. For prostate cancer, previous studies suggest a beneficial role of …
Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019
G Gandaglia, P Albers, PA Abrahamsson, A Briganti… - European urology, 2019 - Elsevier
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …
Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial
Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP)
reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality …
reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality …
[HTML][HTML] What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort
JM Norris, LMC Echeverria, SRJ Bott, LC Brown… - European urology, 2020 - Elsevier
Background All risk stratification strategies in cancer overlook a spectrum of disease. The
Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that …
Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that …